ArriVent BioPharma Reports Third Quarter 2024 Financial Results

18 hours ago · NEWTOWN SQUARE, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated …

CouponFollow Extension

$282
OFF

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

2 weeks from now

17 hours ago · Third Quarter 2024 Financial Results As of September 30, 2024, the Company had cash and cash equivalents of $282.9 million, which is expected to fund operations into 2026.

businessinsider.com

$282
OFF

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

2 weeks from now

18 hours ago · Cash and cash equivalents of $282.9 million as of September 30, 2024. NEWTOWN SQUARE, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. …

marketscreener.com

$1
OFF

Cue Biopharma Reports Third Quarter 2024 Financial Results And …

2 weeks from now

9 hours ago · Third Quarter 2024 Financial Results Collaboration revenue increased by $1.2 million to $3.3 million for the three months ended September 30, 2024, from $2.1 million for …

businessinsider.com

$33
OFF

Zenas BioPharma Reports Third Quarter 2024 Financial Results

2 weeks from now

2 days ago · Research and development (R&D) expenses were $33.5 million for the quarter ended September 30, 2024, compared to $9.4 million for the quarter ended September 30, …

nasdaq.com

$282
OFF

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

2 weeks from now

1 day ago · ArriVent BioPharma (Nasdaq: AVBP) reported Q3 2024 financial results with cash and cash equivalents of $282.9 million, expected to fund operations into 2026. The company …

stocktitan.net

$258
OFF

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial

2 weeks from now

2 days ago · Third Quarter 2024 Financial Results . Cash Balance. As of Sept. 30, 2024, cash, cash equivalents and marketable securities totaled $258.9 million, compared to cash, cash …

globenewswire.com

12%
OFF

Mereo BioPharma Reports Third Quarter 2024 Financial Results …

2 weeks from now

2 days ago · Third Quarter 2024 Financial Results Total research and development (R&D) expenses decreased by $0.4 million, or 12%, from $3.6 million in the third quarter of 2023 to …

businessinsider.com

FAQs about ArriVent BioPharma Reports Third Quarter 2024 Financial Results Coupon?

What did arrivent Biopharma report in third quarter 2024?

ArriVent BioPharma Reports Third Quarter 2024 Financial Results ArriVent BioPharma, Inc. Thu, Nov 14, 2024, 8:00 AM10 min read In This Article: AVBP ArriVent BioPharma, Inc. Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases ...

Who is arrivent Biopharma?

NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, t... ...

What are arrivent Biopharma's current assets?

ARRIVENT BIOPHARMA, INC. BALANCE SHEETS (in thousands, except share and per share data) (Unaudited) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents 282,855 150,389 Prepaid expenses and other current assets 9,543 9,579 Total current assets 292,398 159,968 Right of use assets – operating leases 187 291 ...

What happened to Mereo BioPharma Group plc?

LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. ...

What did Sutro Biopharma do in Q3 2024?

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the third quarter of 2024 and its recent business highlights. ...

Will arrivent Biopharma go public?

ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. ArriVent BioPharma has filed to go public with an IPO on the NASDAQ. ...